Bionomics (BNOX) Stock Price, News & Analysis

-0.02 (-1.99%)
(As of 05:20 PM ET)
Today's Range
50-Day Range
52-Week Range
24,635 shs
Average Volume
198,373 shs
Market Capitalization
$7.83 million
P/E Ratio
Dividend Yield
Price Target

Bionomics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
837.6% Upside
$9.00 Price Target
Short Interest
3.17% of Shares Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($2.59) to ($4.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.22 out of 5 stars

BNOX stock logo

About Bionomics Stock (NASDAQ:BNOX)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

BNOX Stock Price History

BNOX Stock News Headlines

At first glance, this chart looks like nonsense…
We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Bionomics Provides a Review of 2023 and of 2024 Plans
Bionomics Ltd ADR BNOX
Bionomics Limited (BNOX)
Why Is Bionomics (BNOX) Stock Up 347% Today?
Bionomics Ltd: Quarterly Activities and Cashflow Report
See More Headlines
Receive BNOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$2.73 per share


Free Float
Market Cap
$7.83 million
Not Optionable
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Spyridon Papapetropoulos M.D. (Age 51)
    Ph.D., CEO, President & Director
    Comp: $498.92k
  • Mr. Adrian Hinton BEC (Age 71)
    F.C.A., Financial Controller
    Comp: $193.97k
  • Mr. Timothy M. Cunningham CPA (Age 61)
    M.B.A., Chief Financial Officer
  • Prof. Paul Rolan D.C.P.S.A.
    F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Consultant Chief Medical Officer of Clinical Neuroscience
  • Dr. Julie Kerner Ph.D.
    Senior Vice President of Business Operations
  • Ms. Suzanne Irwin B.Com.
    FCIS, Company Secretary

BNOX Stock Analysis - Frequently Asked Questions

Should I buy or sell Bionomics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bionomics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BNOX shares.
View BNOX analyst ratings
or view top-rated stocks.

What is Bionomics' stock price target for 2024?

2 equities research analysts have issued 1 year target prices for Bionomics' stock. Their BNOX share price targets range from $8.00 to $10.00. On average, they expect the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 837.6% from the stock's current price.
View analysts price targets for BNOX
or view top-rated stocks among Wall Street analysts.

How have BNOX shares performed in 2024?

Bionomics' stock was trading at $1.48 on January 1st, 2024. Since then, BNOX stock has decreased by 35.1% and is now trading at $0.9599.
View the best growth stocks for 2024 here

Are investors shorting Bionomics?

Bionomics saw a increase in short interest in March. As of March 31st, there was short interest totaling 258,400 shares, an increase of 344.0% from the March 15th total of 58,200 shares. Based on an average daily volume of 213,800 shares, the short-interest ratio is presently 1.2 days.
View Bionomics' Short Interest

When is Bionomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024.
View our BNOX earnings forecast

When did Bionomics IPO?

Bionomics (BNOX) raised $20 million in an initial public offering (IPO) on Thursday, December 16th 2021. The company issued 1,622,000 shares at a price of $12.35 per share.

How do I buy shares of Bionomics?

Shares of BNOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BNOX) was last updated on 4/22/2024 by Staff

From Our Partners